Choose your region:

How does particle size influence drug formulation and bioavailability?

Particle size directly influences drug formulation by controlling how quickly and completely an active ingredient dissolves and becomes available to the body. Smaller particles have a greater surface area relative to their volume, which accelerates dissolution and can significantly improve the absorption of poorly soluble compounds. The sections below explore the key questions pharmaceutical researchers and formulation scientists encounter when working with particle size across different drug delivery contexts.

How does particle size affect drug solubility and dissolution rate?

Smaller drug particles dissolve faster because they expose more surface area to the surrounding solvent or biological fluid. This relationship is described by the Noyes-Whitney equation, which shows that dissolution rate increases as particle size decreases. For poorly water-soluble compounds, reducing particle size is one of the most direct strategies to improve dissolution performance without altering the molecule itself.

When a drug particle is reduced from the millimeter range to the micrometer or nanometer range, the surface-area-to-volume ratio increases dramatically. More surface area means more contact between the drug and the dissolution medium, which drives faster and more complete dissolution. This is especially relevant for compounds classified as BCS Class II or Class IV, where solubility is the limiting factor for absorption.

It is important to note that solubility and dissolution rate are related but distinct. Particle size reduction primarily accelerates the rate at which a compound dissolves. Intrinsic solubility, determined by the compound’s chemical structure, remains constant. However, for practical purposes in formulation research, faster dissolution often translates into higher apparent solubility under physiologically relevant conditions.

What is the relationship between particle size and oral bioavailability?

Particle size and oral bioavailability are closely linked for poorly soluble drugs: smaller particles dissolve more rapidly in the gastrointestinal tract, increasing the concentration of dissolved drug available for absorption across the intestinal membrane. For well-soluble compounds, particle size has a much smaller effect on bioavailability because dissolution is not the rate-limiting step.

For research into oral drug delivery, this relationship is a central consideration during formulation development. A compound that shows strong pharmacological activity in vitro may underperform in vivo if its particle size leads to incomplete dissolution before it reaches the absorption window in the small intestine. Reducing particle size is therefore not just a processing choice but a strategy that directly affects the translational relevance of preclinical research.

The effect is most pronounced in the fasted state, when gastrointestinal fluid volumes are low and dissolution conditions are more challenging. In the fed state, the presence of bile salts and increased fluid volume can partially compensate for larger particle sizes, which is why fed-versus-fasted studies are a standard part of formulation research.

What particle size range is optimal for different drug delivery routes?

The optimal particle size range depends entirely on the intended delivery route. Each route places different physical and biological constraints on the drug particle, and formulation researchers must tailor particle size accordingly.

  • Oral solid dosage forms: Particle sizes in the range of 1 to 100 micrometers are typical, with micronization to 1 to 10 micrometers used for poorly soluble compounds to maximize dissolution.
  • Inhalation (pulmonary delivery): Particles must reach the deep lung, requiring an aerodynamic diameter of approximately 1 to 5 micrometers. Particles outside this range are either exhaled or deposited in the upper airways.
  • Injectable suspensions: Particle size must be carefully controlled to prevent aggregation and ensure syringeability; sub-micron and nanoparticle formulations are often used for intravenous applications.
  • Topical and transdermal formulations: Smaller particles can improve skin penetration and uniform distribution within the formulation base.
  • Nasal delivery: Particles in the 10 to 50 micrometer range are generally preferred to promote deposition on the nasal mucosa rather than inhalation into the lungs.

Understanding these ranges is foundational for formulation scientists, as selecting the wrong particle size for a given route can compromise both efficacy and safety in research models.

How do pharmaceutical manufacturers reduce particle size?

Pharmaceutical manufacturers reduce drug particle size primarily through mechanical milling, wet milling, and high-pressure homogenization. The choice of method depends on the compound’s physicochemical properties, the target particle size, and the required production scale.

The most established techniques include:

  1. Jet milling (air jet milling): Uses high-velocity compressed air to create particle-on-particle collisions, achieving micronized particles in the 1 to 10 micrometer range without introducing heat or solvent.
  2. Ball milling and media milling: Mechanical grinding using grinding media; wet media milling is widely used to produce nanosuspensions by dispersing the drug in a liquid medium with stabilizers.
  3. High-pressure homogenization: Forces a drug suspension through a narrow gap at high pressure, generating intense shear and cavitation forces that break particles down to the nanometer scale.
  4. Spray drying: Converts a liquid drug solution or suspension into a dry powder with controlled particle morphology and size, often used in combination with amorphous solid dispersion strategies.

Each technique has trade-offs in terms of scalability, heat sensitivity, and the potential for introducing impurities. In research settings, small-scale milling and homogenization equipment allows scientists to generate material for early-stage studies before committing to a full-scale process.

What are the risks of making drug particles too small?

Making drug particles too small introduces a range of physical and chemical stability risks. At the nanometer scale, particles have very high surface energy, which drives aggregation, crystal growth, and changes in solid-state form. These instabilities can alter dissolution behavior and compromise the reproducibility of research findings.

Key risks associated with over-reduction of particle size include increased reactivity at the particle surface, which can accelerate chemical degradation pathways such as oxidation or hydrolysis. Nanoparticles may also interact differently with biological membranes and cellular uptake mechanisms, which can be either an intended feature or an unintended complication depending on the research context.

From a processing perspective, very fine particles are often more difficult to handle, flow poorly, and may require additional excipients or formulation strategies to maintain physical stability. For inhalation research, particles below 1 micrometer are generally exhaled rather than deposited, making them ineffective for pulmonary delivery despite their small size.

Selecting the appropriate particle size is therefore a balance: small enough to achieve the desired dissolution or delivery performance, but not so small that stability and manufacturability are compromised.

How is particle size measured and controlled in drug development?

Particle size in drug development is measured using techniques such as laser diffraction, dynamic light scattering, and microscopy, each suited to different size ranges and sample types. Controlling particle size requires a combination of well-defined manufacturing processes, appropriate analytical methods, and specification limits established during formulation development.

Laser diffraction is the most widely used technique for measuring particle size distributions in the micrometer range, providing rapid results across a broad size range. Dynamic light scattering is preferred for nanoparticle characterization, measuring the hydrodynamic diameter of particles in suspension. Scanning electron microscopy and atomic force microscopy offer direct visual confirmation of particle morphology and size, which is particularly valuable when shape as well as size affects performance.

Control of particle size is embedded into the development process through design of experiments, where process parameters such as milling time, speed, and temperature are systematically varied to understand their effect on the final particle size distribution. This approach supports the establishment of robust manufacturing conditions and is consistent with quality-by-design principles widely applied in pharmaceutical development.

Ongoing monitoring during production typically involves in-process measurements at defined intervals, with release testing confirming that the final batch meets the agreed specifications before use in research studies.

How ChemSPX supports particle size research in pharmaceutical formulation

For formulation researchers and laboratory scientists in the Benelux working on drug particle size and pharmaceutical bioavailability studies, having the right instrumentation is essential for generating reliable, reproducible data. ChemSPX supplies high-end laboratory instruments specifically suited to chemical synthesis and formulation research workflows, supporting teams from early-stage development through to process optimization.

  • Expert advice from Sales Engineers and Product Specialists with deep knowledge of formulation and synthesis instrumentation
  • Support across the full workflow, from instrument selection and demonstration to installation and application development
  • Certified service and support for IQ/OQ installations, calibrations, and validations in line with GMP, GLP, and 21 CFR Part 11 requirements
  • Local presence in the Netherlands and Belgium, ensuring responsive support for Benelux-based research teams

Whether you are optimizing a particle size reduction process, evaluating analytical methods, or scaling up a formulation workflow, ChemSPX’s team is ready to help you find the right solution. Contact ChemSPX to discuss your laboratory instrumentation needs.

Veelgestelde vragen

Can particle size reduction alone be enough to make a poorly soluble drug commercially viable?

Particle size reduction is a powerful tool, but it is rarely sufficient on its own for highly insoluble compounds. For BCS Class II and Class IV drugs with very low intrinsic solubility, micronization or nanonization may need to be combined with complementary strategies such as amorphous solid dispersions, lipid-based formulations, or co-crystal engineering to achieve therapeutically meaningful bioavailability. The right approach depends on the compound’s physicochemical profile, dose requirements, and target patient population, which is why early-stage solubility and dissolution screening is so important before committing to a particle size reduction strategy.

How do I know which particle size reduction technique is the right starting point for my compound?

The best starting point depends on three key factors: the target particle size range, the compound’s sensitivity to heat and mechanical stress, and the scale of material needed for your research phase. Jet milling is a practical first choice for heat-sensitive compounds requiring micron-range particles without solvent, while wet media milling is preferred when nanosuspensions are the target. Before selecting a technique, it is worth conducting a basic physicochemical characterization — including melting point, hygroscopicity, and crystal form — to identify any processing risks early and avoid costly reformulation later.

What is the most common mistake researchers make when developing a particle size specification?

One of the most frequent mistakes is setting a particle size specification based solely on the manufacturing process rather than linking it explicitly to dissolution performance and in vivo relevance. A specification that is too broad may allow batches with significantly different bioavailability profiles to pass release testing, introducing variability into preclinical or clinical studies. Best practice is to establish a biorelevant dissolution-linked specification early in development, using a design of experiments approach to understand how the particle size distribution affects dissolution rate under physiologically relevant conditions.

How does particle size affect the physical stability of a drug formulation during storage?

Smaller particles, particularly in the nanometer range, have significantly higher surface energy, which makes them thermodynamically unstable and prone to Ostwald ripening, aggregation, and crystal growth during storage. These changes can shift the particle size distribution over time, directly affecting dissolution performance and potentially compromising the reproducibility of your research data. Stabilizers such as polymers and surfactants are routinely added to nanosuspensions to inhibit particle growth, and formulations should be stress-tested under accelerated storage conditions early in development to identify stability risks before they become a problem in later-stage studies.

Is laser diffraction always the right analytical method for measuring particle size in formulation research?

Laser diffraction is the workhorse technique for particles in the micrometer range and offers fast, reproducible results with good statistical representation of the bulk sample, making it well suited to most oral and inhalation formulation workflows. However, it has limitations: it assumes spherical particles and may not accurately capture the true size of highly elongated or irregular crystals. For nanoparticles below approximately 1 micrometer, dynamic light scattering provides better resolution, while electron microscopy is invaluable when particle morphology — not just size — is relevant to performance. Using a combination of techniques gives a more complete and defensible characterization dataset.

What should I consider when scaling up a particle size reduction process from lab to pilot scale?

The key challenge in scale-up is maintaining the same particle size distribution and solid-state properties achieved at lab scale, as process parameters such as milling energy, residence time, and temperature can behave very differently in larger equipment. It is essential to identify the critical process parameters early using a design of experiments approach and to establish in-process monitoring protocols so deviations are caught before they affect the final batch. Working with equipment suppliers and formulation specialists who have experience across both scales can significantly reduce the risk of unexpected performance differences between your research and production batches.

How does particle shape interact with particle size to influence drug performance?

Particle shape is often overlooked but can significantly influence dissolution rate, powder flow, compressibility, and aerodynamic behavior — particularly for inhalation formulations where aerodynamic diameter, not just geometric size, determines lung deposition. For example, needle-like or plate-like crystals of the same nominal size as spherical particles may behave very differently during milling, blending, and dissolution. Microscopy techniques such as scanning electron microscopy or automated image analysis are the most reliable way to characterize shape alongside size, and formulation scientists should consider both parameters when setting specifications and evaluating process changes.

Gerelateerde artikelen

Deze inhoud is gegenereerd met behulp van AI en kan fouten bevatten.

Contact our Xperts

Prefer to give us a call?

Belgium & Luxembourg
+32 (02)2 334 22 70

Please select your country

By selecting your country, we can show you the products that are available for you and your organisation.